Introduction:

Spinal Muscular Atrophy Market was valued at US$ 1.4 billion in 2024 and is projected to grow at a CAGR of 14.8% to reach US$ 5.6 billion by 2034.

Spinal muscular atrophy (SMA) is genetic rare disease, affecting part of the nervous system which controls voluntary muscle movement. SMA involves loss of motor neuron in spinal cord making muscles weaker and causes problems with its movement. There are four types of spinal muscular atrophy which starts at different stages of ages. Spinal muscular atrophy (SMA) may be a rare neuromuscular disorder that leads to the loss of motor neurons and progressive muscle wasting. It’s usually diagnosed in infancy or infancy and if left untreated it's the foremost common genetic explanation for sudden infant death syndrome. It’s going to also appear later in life then have a milder course of the disease. The common feature is progressive weakness of voluntary muscles, with arm, leg and respiratory muscles being affected first. Associated problems may include poor head control, difficulties swallowing, scoliosis, and joint contractures. The age of onset and therefore the severity of symptoms form the idea of the normal classification of spinal muscular atrophy into variety of types. Spinal muscular atrophy is due to an abnormality (mutation) within the SMN1 gene which encodes SMN, a protein necessary for survival of motor neurons. Loss of those neurons within the medulla spinal is prevents signaling between the brain and skeletal muscles. Another gene, SMN2, is taken into account a disease modifying gene, since usually the more the SMN2 copies, the milder is that the disease course. The diagnosis of SMA is predicated on symptoms and confirmed by genetic testing.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Due to many ongoing researches

Currently, there is no cure for SMA; however, research is going on to find various possible new treatments. However, treatment and support is available to manage the symptoms and help people with SMA to have the best possible quality of life. In December 2016 U.S. Food and Drug Administration (FDA) approved nusinersen (Spinraza), the first drug to be approved to treat children (including newborns) and adults with SMA. Currently, in August 2018, a phase II clinical trials studies are testing the effectiveness of Mestinon (pyridostigmine), an approved medicine for myasthenia gravis is being studying to treat fatigue in people with spinal muscular atrophy (SMA) types II, III, and IV.

Increasing cases of spinal muscular atrophy

Moreover, increasing cases of spinal muscular atrophy worldwide, coupled with increasing number of ongoing clinical trial studies and growing research and development funding by government as well as various healthcare regulatory bodies are some among the major factors expected to drive growth of the global spinal muscular atrophy market, over the forecast period.

The global spinal muscular atrophy market has been segmented on the basis of disease type, age, treatment, and region.

On the basis of disease type, the spinal muscular atrophy market is segmented into Type I, Type II, Type III, and Type IV. On the basis of age, spinal muscular atrophy market segmented into infants and adults. Further, treatment segment for spinal muscular atrophy market segmented into drug therapy and gene therapy. On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.

Regional Insights:

For detailed understanding of market dynamics,on the basis of region, the target market is sun segmented into North America, Asia Pacific, Europe, Latin America and Middle East & Africa. North America is expected to dominate the spinal muscular atrophy market. Factors responsible for growth of the market includes substantial rise in the awareness among the people regarding various risk factors to cause multiple sclerosis. In addition, high diagnostic rate in the U.S. which leads to significant rise in prescription rates in this region to gain the dominance in the market. Asia Pacific region offers lucrative growth opportunities in spinal muscular atrophy market, owing to increasing engagement of key players by collaboration with local key players in attempt to capture the market by offering novel treatment therapy, in the region. 

Report Scope:

Attribute	Details
Market Size 2024	US$ 1.4 billion
Projected Market Size 2034	US$ 5.6 billion
CAGR Growth Rate	14.8%
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Disease Type: Type I, Type II, Type III, and Type IV By Age: Infant and Adult By Treatment: Drug Therapy and Gene Therapy
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Spinal Muscular Atrophy Market report based on disease type, age, treatment, and region:

Detailed Segmentation:

Spinal Muscular Atrophy Market, By Disease Type:

• Type I
• Type II
• Type III
• Type IV

Spinal Muscular Atrophy Market, By Age:

• Infant
• Adult

Spinal Muscular Atrophy Market, By Treatment:

• Drug Therapy
• Gene Therapy

Spinal Muscular Atrophy Market, By Region:

• North America
  • Middle East & Africa
    • Middle East & Africa Spinal Muscular Atrophy Market, By Disease Type
    • Middle East & Africa Spinal Muscular Atrophy Market, By Age
    • Middle East & Africa Spinal Muscular Atrophy Market, By Treatment
    • Middle East & Africa Spinal Muscular Atrophy Market, By Country
      • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • Latin America Spinal Muscular Atrophy Market, By Disease Type
    • Latin America Spinal Muscular Atrophy Market, By Age
    • Latin America Spinal Muscular Atrophy Market, By Treatment
    • Latin America Spinal Muscular Atrophy Market, By Country
      • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • Asia Pacific Spinal Muscular Atrophy Market, By Disease Type
    • Asia Pacific Spinal Muscular Atrophy Market, By Age
    • Asia Pacific Spinal Muscular Atrophy Market, By Treatment
    • Asia Pacific Spinal Muscular Atrophy Market, By Country
      • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • Europe Spinal Muscular Atrophy Market, By Disease Type
    • Europe Spinal Muscular Atrophy Market, By Age
    • Europe Spinal Muscular Atrophy Market, By Treatment
    • Europe Spinal Muscular Atrophy Market, By Country
      • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • North America Spinal Muscular Atrophy Market, By Disease Type
  • North America Spinal Muscular Atrophy Market, By Age
  • North America Spinal Muscular Atrophy Market, By Treatment
  • North America Spinal Muscular Atrophy Market, By Country
    • The U.S.
    • Canada

The Key players operating in the global spinal muscular atrophy market includes Biogen, Cytokinetics, Inc., F. Hoffmann-La Roche, Novartis AG, Pfizer Inc., and Ionis Pharmaceuticals, Inc.

Recent Development:

• In November 2023, A new test to identify babies more with Spinal Muscular Atrophy (SMA) is being rolled out in across Wessex. The screening, part of a study run by Oxford University, will see 8000 babies tested over the next 14 months.If identified at birth SMA can be treated and give newborns the best chance of living long and healthy lives.The screening is administered via a prick to the heel, which allows scientists to test the blood of the baby for the genetic markers.
• In June 2023, Biogen Inc. announced new SPINRAZA® (nusinersen) data aimed at answering critical questions for the spinal muscular atrophy (SMA) community. The data were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA this week in Orlando, Fla.

• Biogen
  •  Ionis Pharmaceuticals, Inc.
  • Company Overview
  • Financial Performance
  • Key Highlights
  • Product Portfolio
  • Pfizer Inc.
    • • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
  • Novartis AG
    • • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
  • F. Hoffmann-La Roche
    • • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
  • Cytokinetics, Inc.
    • • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
  • • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
3. Market Preview
   • Executive Summary
   • Key Findings—Global Outlook for Spinal Muscular Atrophy Strategies
     • Key Questions this Study will Answer
     • Market Snippet, By Disease Type
     • Market Snippet, By Age
     • Market Snippet, By Treatment
     • Market Snippet, By Region
   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Market Segmentation, By Disease Type,  2024 – 2034, (US$ Bn)
   • Overview                          
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
     • Y-o-Y Growth Analysis (%), 2024 – 2034
     • Segment Trends
   • Type I
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
   • Type II
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
   • Type III
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
   • Type IV
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
6. Market Segmentation, By Age,  2024 – 2034, (US$ Bn)
   • Overview                
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
     • Y-o-Y Growth Analysis (%), 2024 – 2034
     • Segment Trends
   • Infants
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
   • Adults
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
7. Market Segmentation, By Treatment, 2024 – 2034, (US$ Bn)
   • Overview                   
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
     • Y-o-Y Growth Analysis (%), 2024 – 2034
     • Segment Trends
   • Drug Therapy
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
   • Gene Therapy
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
8. Global Market, By Region, 2024 – 2034, (US$ Bn)
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
     • Y-o-Y Growth Analysis (%), 2024 – 2034
     • Regional Trends
   • North America
     • Market Size and Forecast (US$ Bn), By Disease Type, 2024 – 2034
     • Market Size and Forecast (US$ Bn), By Age, 2024 – 2034
     • Market Size and Forecast (US$ Bn), By Treatment, 2024 – 2034
     • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
       • U.S.
       • Canada
   • Europe
     • Market Size and Forecast (US$ Bn), By Disease Type, 2024 – 2034
     • Market Size and Forecast (US$ Bn), By Age, 2024 – 2034
     • Market Size and Forecast (US$ Bn), By Treatment, 2024 – 2034
     • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
       • UK
       • France
       • Germany
       • Russia
       • Italy
       • Rest of Europe
   • Asia Pacific
     • Market Size and Forecast (US$ Bn), By Disease Type, 2024 – 2034
     • Market Size and Forecast (US$ Bn), By Age, 2024 – 2034
     • Market Size and Forecast (US$ Bn), By Treatment, 2024 – 2034
     • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
       • India
       • Japan
       • South Korea
       • China
       • Rest of Asia Pacific
   • Latin America
     • Market Size and Forecast (US$ Bn), By Disease Type, 2024 – 2034
     • Market Size and Forecast (US$ Bn), By Age, 2024 – 2034
     • Market Size and Forecast (US$ Bn), By Treatment, 2024 – 2034
     • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
       • Brazil
       • Mexico
       • Rest of Latin America
   • Middle East & Africa
     • Market Size and Forecast (US$ Bn), By Disease Type, 2024 – 2034
     • Market Size and Forecast (US$ Bn), By Age, 2024 – 2034
     • Market Size and Forecast (US$ Bn), By Treatment, 2024 – 2034
     • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
       • GCC
       • Israel
       • South Africa
       • Rest of Middle East
9. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
10. Company Profiles
    • Biogen
      •  
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
    • Cytokinetics, Inc.
      •  
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
    • F. Hoffmann-La Roche
      •  
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
    • Novartis AG
      •  
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
    • Pfizer Inc.
      •  
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
    •  Ionis Pharmaceuticals, Inc.
      •  
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance

The Last Word

• Future Impact
• About Us
• Contact